GSLS in Pictures

Clinical Report: GSLS 2026 Highlights and Myopia Management Advances

Overview

The 2026 Global Specialty Lens Symposium (GSLS) showcased advancements in specialty lenses and myopia management strategies. Key discussions included the efficacy of low-dose atropine and orthokeratology in controlling myopia progression in children.

Background

The management of myopia is critical due to its increasing prevalence and potential long-term visual impairment. Recent consensus guidelines emphasize proactive, evidence-based approaches, including pharmacologic and optical interventions. The GSLS serves as a platform for sharing the latest research and clinical practices in specialty lenses and myopia management.

Data Highlights

No numerical data available in the provided source material.

Key Findings

The FDA authorized Essilor Stellest spectacle lenses for myopia control in children aged 6-12.
A randomized trial found 0.04% atropine more effective than 0.01% atropine or OK monotherapy for myopia control.
Combination therapy with orthokeratology and 0.01% atropine shows incremental reduction in axial elongation.
Sequential dosing of atropine (0.01%→0.025%→0.05%) can enhance treatment efficacy.
Evidence supports the use of specialty lenses for irregular corneas and ocular surface disease.

Clinical Implications

Clinicians should consider integrating low-dose atropine and orthokeratology into myopia management strategies for pediatric patients. The recent FDA approval of new spectacle lenses expands treatment options and aligns with current evidence-based guidelines.

Conclusion

The GSLS 2026 highlighted significant advancements in specialty lenses and myopia management, reinforcing the importance of evidence-based approaches in clinical practice.

PentaVision

Contact Lens Spectrum